Hope's Pharmacy Coordinator Carla’s persistence turned a "no" into a "no problem" for our medical patients last month. Click to read more. We’ve been receiving more and more calls from patients needing the Shingrix and Pneumovax vaccines. Shingles and Pneumonia are both disruptive and painful ailments—and both preventable. In the past, getting these vaccines required a big cash commitment up front, which doesn't work for a nonprofit like Hope Clinic. Just another example of good health being a privilege reserved for wealthy patients and moneyed providers. Carla decided to "dig in." There had to be a way to get our patients their vaccines! And surely enough, with some persistence, she found one! Now Hope Clinic give these two very critical vaccines to our older patient population. Excellent job, Carla!
Hope Clinic’s Post
More Relevant Posts
-
If you missed the live event, I encourage you watch the replay of International Pharmaceutical Federation (FIP)'s "Preparing for Winter: Pharmacy-based Vaccination Strategies" digital event. A panel of experts in #vaccine immunology, pharmacy, and policy discuss winter-ready vaccination strategies to meet the unique challenges posed by the winter cold season as well as best practices for addressing the increased incidence of #flu, #rsv, and #covid19 in at-risk populations. #fightflu #getvaccinated https://lnkd.in/eV4b5-mq
-
-
NAHN is a national organization representing the voice of Hispanic nurses.
Join NAHN & the Covid-19 Vaccine Education and Equity Project for a virtual learning experience, September 25 at 8:00 pm Eastern! REGISTER at bit.ly/NAHNcrearconfianza. Last year, after conducting a study with more than 700,000 patients, the CDC reported that Black patients were 36% less likely to be prescribed an Oral antiviral than white patients, and Hispanics were 30% less likely to get the drug. As we enter the cold & flu season, there is a lot of talk about the updated Flu & COVID-19 vaccines, and Oral Antivirals continue to create confusion among the population in regard to eligibility and treatment in spite of last year's FDA & CDC approval. However, if patients are not able to get vaccinated, what other forms of treatment are they offered? This session will answer your questions on: What are antivirals? When are they recommended for treatment? Do they produce side-effects? Who is eligible to take them? Can I purchase them in advance? Register at https://lnkd.in/gd7ddhpn.
-
-
NAHN is a national organization representing the voice of Hispanic nurses.
Have you registered yet for Monday's webinar with NAHN & the Covid-19 Vaccine Education and Equity Project? Join us on September 25 at 8:00 pm Eastern! Register: bit.ly/NAHNcrearconfianza. Last year, after conducting a study with more than 700,000 patients, the CDC reported that Black patients were 36% less likely to be prescribed an Oral antiviral than white patients, and Hispanics were 30% less likely to get the drug. As we enter the cold & flu season, there is a lot of talk about the updated Flu & COVID-19 vaccines, and Oral Antivirals continue to create confusion among the population in regard to eligibility and treatment in spite of last year's FDA & CDC approval. However, if patients are not able to get vaccinated, what other forms of treatment are they offered? This session will answer your questions on: What are antivirals? When are they recommended for treatment? Do they produce side-effects? Who is eligible to take them? Can I purchase them in advance? Featuring speaker Hector Cabrera, MD.
-
-
Clinical Biochemist | Dual Master's in Digital Health and Public Health Management | COVID-19 Expert | Leader in Clinical Diagnostics | Published Scientist.
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023 #COVIDResearch #VaccineEfficacy #PublicHealthInsights #MedicalStudies #CDCFindings #COVIDPrevention #HealthScience #ThromboembolicProtection #ResearchUpdate #BivalentVaccine #PublicSafety #StayInformed #HealthcareNews #CDCReport #VaccineProgress #InfectiousDiseasePrevention
-
Merck announced yesterday that the U.S. FDA has approved its next-gen vaccine, Capvaxive, to protect adults against pneumococcal disease. What is Pneumococcal Disease? It can cause serious infections, including pneumonia, affecting various body parts. With around 100 different strains, it’s crucial to have robust protection. Why Capvaxive? · Targets 21 serotypes of the bacteria · Proven effective across diverse adult populations · Wholesale price: $287 per dose · Likely no out-of-pocket cost with CDC recommendation When Available? Late summer, pending CDC advisers' recommendation expected later this month. FDA Approval: · Approved for adults 18+ years · Who’s at Risk? · Children <5 and adults 65+ are more vulnerable. Merck also offers Vaxneuvance (for 6 weeks and older) and Pneumovax 23 (for adults 50+ and high-risk individuals 2+ years). With Capvaxive, Merck aims to outpace Pfizer’s Prevnar 20, approved in 2021. https://lnkd.in/dCKxdpD6 #SECORA #FDAApproval #Vaccine #Capvaxive #Merck #PneumococcalDisease #PneumoniaPrevention #CDC #PharmaNews
US FDA approves Merck's pneumococcal vaccine for adults
reuters.com
